Market Scenario:
Irritable bowel syndrome (IBS) is a common disorder that affects the digestive system. IBS is characterized by symptoms such as stomach cramps, bloating, diarrhea, and constipation, which impacts one’s everyday life. Although the cause of IBS is unknown, but few factors that cause IBS are severe infection, inflammation in the intestines, muscle contractions in the intestine, changes in bacteria in the gut, and abnormalities in the nerves. Rising prevalence of gastrointestinal diseases and disorder, geriatric population, unhealthy diet, anxiety, depression, and changing lifestyle in Americas are the key drivers of the Americas IBS market.
Furthermore, increasing consumer awareness about the irritable bowel syndrome increase the footfall of patient in clinics and hospitals. Furthermore, increasing spending in the healthcare domain fuelling the growth of the IBS treatment market. According to the Centers for Medicare & Medicaid Services, in 2015, the U.S. healthcare spending increased by 5.8% reaching USD 3.2 trillion. In 2016, the healthcare spending in North America had increased to some extent.
However, strict FDA regulations and unsatisfactory effectiveness of the treatment may hinder the growth of Americas IBS treatment market during forecast period.
Get Exclusive Sample Report @https://www.marketresearchfuture.com/sample_request/5555
Segmentation:
The Americas IBS treatment market is segmented on the basis of types, drugs type, and end user.
On the basis the types, it is segmented into IBS-D, IBS-C, IBS-M.
On the basis of the drugs type, it is segmented into lubiprostone, linaclotide, eluxadoline, rifaximin, alosetron, and others.
On the basis of the end users, it is segmented into hospitals, clinics, and research laboratories.
Intended Audience:
• Pharmaceutical Companies
• Medical Devices Companies
• Research and Development (R&D) Companies
• Market Research and Consulting Service Providers
• Potential Investors
Key Findings:
The Americas IBS treatment market is estimated at USD 1,959.5 million in 2016.
IBS-C is the fastest growing segment, which is projected grow at a CAGR of 9.6% during the forecast period 2017-2023.
Linaclotide is the fastest growing drugs type segment, which is expected to USD 1,164.8 million by 2023.
The United States captured the largest market of Americas and is expected to USD 2,660.9 million by 2023.
Regional Analysis:
The Americas region is divided into North America and South America. North America command the largest market of IBS treatment owing to the well presence of health care structure, government support, various research and development programs, increasing sensitivity and specificity for diagnosing IBS, aware and concerned individual, and presence of well-developed clinical laboratories. Moreover, presence of strong economic condition, and focus of research institutions on updating technology for new and advanced IBS treatment fuel the growth of market in this region. Also, the countries in this region have multiple companies which are involved in the IBS treatment business. North America is further divided into the U.S. and Canada. Both of these countries have good economic growth and great standard of living. According to a report published by the International Foundation for Functional Gastrointestinal Disorders, in 2016, functional gastrointestinal (GI) and motility disorders are the most common GI disorders which accounted for 1 in 4 people or more in the United States.
Key Players in the Americas GERD & NERD Treatment Market
Some of the key players in this market are Allergan Plc (Ireland), Sucampo Pharmaceuticals (U.S.), Ironwood Pharmaceuticals, Inc. (U.S.), Astellas Pharma Inc. (Japan), Valeant Pharmaceuticals (Canada), Abbott Laboratories (U.S.), Synergy Pharmaceuticals, Inc. (U.S.), Ardelyx, Inc. (U.S.), Nestle (Switzerland), Sebela Pharmaceuticals (Ireland), Probi (Sweden), Alfasigma USA, Inc. (Italy), RedHill Biopharma Ltd. (Israel), AstraZeneca (U.K), Ipsen (France), Novartis AG (Switzerland), Takeda Pharmaceutical Company Ltd (Japan), Synthetic Biologics, Inc. (U.S.), Protagonist Therapeutics Inc. (U.S.), Pfizer Inc (U.S.), Lexicon Pharmaceuticals, Inc. (U.S.), Innovate Biopharmaceuticals (U.S.), 4D pharma plc (U.K).
Get Your Customized Report @https://www.marketresearchfuture.com/reports/ibs-treatment-market-5555
Table of Content:
1 REPORT PROLOGUE
2 MARKET INTRODUCTION
2.1 Scope Of Study 11
2.2 Research Objective 11
2.3 Assumptions & Limitations 11
2.3.1 Assumptions 11
2.3.2 Limitations 11
2.4 Market Structure 12
3 RESEARCH METHODOLOGY
3.1.1 Primary Research Methodology 14
3.1.2 Data Points Received From The Doctors/ Gastrologist: 14
3.1.3 Data Points Received From The Manufacturer/ Pharmaceutical Companies: 15
3.1.4 Data Points Received From Hospitals, Clinics: 15
3.1.5 Secondary Research Methodology 17
3.1.6 Market Share Analysis 19
3.1.7 Trade Analysis 19
3.1.8 Market Pricing Approach 19
TOC Continued…!
Get Discount @https://www.marketresearchfuture.com/check-discount/5555
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: [email protected]